The company offers a diverse portfolio of more than 115 molecules addressing conditions such as depression, anxiety, Parkinson’s disease, Alzheimer’s disease, epilepsy, and schizophrenia. Neurexapharm has a direct presence in more than 20 countries across Europe and has recently expanded into Latin America and the Middle East, reaching patients in over 50 countries worldwide. 

In December 2024, the company acquired Provigil (modafinil) and Nuvigil (armodafinil), two leading treatments for narcolepsy, expanding its presence in markets including Australia and Mexico. 

Additionally, in December 2024, Neuraxpharm entered into a strategic co-development agreement with Pharmathen to develop long-acting injectable therapies within the psychiatry field. This collaboration aims to provide patients with greater choice and flexibility in managing CNS disorders.